MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-05-2026
Arrowhead Pharmaceuticals EV - Enterprise Value 2011-2026 | ARWR
Annual EV - Enterprise Value Arrowhead Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.02 B | 2.43 B | 2.98 B | 2.91 B | 4.38 B | 7.81 B | 3.64 B | 1.03 B | 268 M | 306 M | 237 M | 200 M | 159 M | 28.5 M | 33.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.81 B | 28.5 M | 2.16 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
540 M | $ 4.14 | 0.36 % | $ 443 M |  USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
43.4 M | $ 8.41 | 4.73 % | $ 230 M |  Israel |
 |
Ardelyx
ARDX
|
1.89 B | $ 6.06 | 1.94 % | $ 1.46 B | USA |
 |
argenx SE
ARGX
|
-2.13 B | $ 752.35 | 0.79 % | $ 25 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
3.64 B | $ 23.83 | 0.85 % | $ 3.03 B | USA |
 |
Aytu BioScience
AYTU
|
-15.2 M | $ 2.65 | -1.12 % | $ 16.6 M | USA |
 |
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | France |
 |
BioCardia
BCDA
|
8.09 M | $ 1.2 | -0.04 % | $ 8 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
2.58 B | $ 9.6 | 6.37 % | $ 1.98 B | USA |
 |
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
10.2 B | $ 9.48 | -3.27 % | $ 613 M | USA |
 |
BioVie
BIVI
|
-12.6 M | $ 1.45 | 2.09 % | $ 2.14 M | USA |
 |
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
7.6 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | USA |
 |
BioLineRx Ltd.
BLRX
|
15 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - |  Russia |
 |
BioMarin Pharmaceutical
BMRN
|
11.9 B | $ 56.49 | 1.78 % | $ 10.8 B | USA |
 |
BioNTech SE
BNTX
|
-4.91 B | $ 92.3 | 1.23 % | $ 27.2 B | Germany |
 |
Allena Pharmaceuticals
ALNA
|
-14.1 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
363 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
4.02 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
197 M | $ 3.04 | 1.54 % | $ 259 M | USA |
 |
BioXcel Therapeutics
BTAI
|
127 M | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Burford Capital Limited
BUR
|
3.22 B | $ 4.54 | 9.54 % | $ 683 M | Britain |
 |
Cabaletta Bio
CABA
|
253 M | $ 3.2 | 7.94 % | $ 322 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
647 M | $ 3.21 | 4.56 % | $ 6.98 B | Israel |
 |
Aravive
ARAV
|
58.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Catalyst Biosciences
CBIO
|
986 M | $ 19.97 | 2.94 % | $ 1.78 B | USA |
 |
Aptose Biosciences
APTO
|
36.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Codexis
CDXS
|
157 M | $ 1.97 | 7.97 % | $ 172 M | USA |
 |
Cerus Corporation
CERS
|
632 M | $ 1.91 | 2.42 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
850 M | $ 15.4 | 6.72 % | $ 928 M | USA |
 |
Coherus BioSciences
CHRS
|
335 M | $ 1.75 | 0.87 % | $ 205 M | USA |
 |
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | Britain |